Centric Compounding Recalls Three Injectable Wellness Products Over Endotoxin Contamination

Nine patients have reported adverse reactions—a figure that represents the known human impact of a nationwide recall affecting three popular injectable wellness treatments distributed across the United States. Centric Compounding LLC has pulled six lots of its 30-milliliter multidose vials from the market following the discovery of elevated endotoxin levels in an active ingredient. The recall targets products shipped directly to patients for home use and to medical professionals for clinical administration, prompting immediate safety warnings across the wellness industry. The affected vials were distributed nationwide, meaning the contaminated products could currently be sitting in residential refrigerators or commercial clinic inventories waiting to be administered.[2][3]

The recall specifically targets compounded intravenous formulations of Glutathione, Myer's Cocktail, and Tri-Immune Boost. These products are widely marketed for immune support, detoxification, and general wellness purposes, and are frequently administered in commercial wellness clinics, medical spas, and concierge medicine practices. The popularity of these IV infusions has grown rapidly in recent years, moving outside of traditional hospital settings and into retail health environments where consumers purchase them as elective wellness upgrades. Because these treatments are administered directly into the bloodstream, any contamination bypasses the body's primary defensive barriers, making the purity of the injectable solution a critical safety requirement.[1][5]

Endotoxins introduced directly into the bloodstream pose an immediate and severe health risk. The Food and Drug Administration announced the recall on September 13, 2026, warning that contaminated intravenous products can trigger high fever, dangerously low blood pressure, and septic shock. Endotoxins are toxic substances bound to the bacterial cell wall that are released when the bacterium ruptures or disintegrates. When present in intravenous medications, they can provoke a rapid and aggressive immune response that requires emergency medical intervention to stabilize the patient's vital signs.[5]

Centric Compounding initiated the recall after receiving nine direct reports of patients experiencing fever, chills, chest pain, nausea, vomiting, headache, and malaise. The company explicitly warned that the elevated endotoxin levels could lead to "significant medical events, including fevers, hypotension, inflammatory reactions, anaphylactic shock and death." The contamination was traced specifically to a Glutathione active pharmaceutical ingredient used during the compounding process. Identifying the source of the contamination allowed the pharmacy to isolate the specific six lots that pose a danger to consumers.[3]

Consumers and healthcare providers in possession of the affected Glutathione, Myer's Cocktail, or Tri-Immune Boost vials are instructed to stop using them immediately and discard the remaining product. Centric Compounding has stated it is actively arranging replacements for all recalled items. Patients who have recently received an IV infusion containing these products and are experiencing symptoms such as chest pain, fever, or severe nausea should seek immediate medical attention. The rapid onset of symptoms associated with endotoxin exposure means that adverse reactions typically present shortly after the infusion is administered.[3]

This incident highlights the distinct regulatory environment surrounding compounded medications. Unlike commercially available, FDA-approved drugs, compounded formulations are customized to fill specific medical needs but do not undergo the same standardized manufacturing scrutiny. Compounding pharmacies play a vital role in the healthcare system by creating tailored dosages or removing allergenic ingredients for specific patients. However, the customized nature of the production process means these facilities operate under different oversight frameworks than massive pharmaceutical manufacturing plants, placing a heavier reliance on internal quality control measures.[5]

The agency has repeatedly raised concerns about oversight gaps in the compounding pharmacy industry. As IV wellness infusions have transitioned from traditional medical settings into commercial spa environments, clinical oversight has become increasingly decentralized. This shift places a heavier burden on consumers to verify the safety and origin of their elective treatments. The 2012 New England Compounding Center meningitis outbreak, which killed 76 people and sickened hundreds, remains the starkest historical example of the risks associated with compounding quality control failures, driving ongoing debates about the appropriate level of federal regulation.[5]

The immediate priority for public health officials is ensuring that all contaminated vials are removed from circulation before further adverse events occur. Medical spas and concierge practices are currently auditing their inventories to identify the six recalled lots. Patients who regularly receive IV wellness treatments are advised to ask their providers about the source and batch numbers of the medications being administered. The resolution of this recall will depend on Centric Compounding's ability to trace all distributed vials and implement stricter testing protocols for its active pharmaceutical ingredients moving forward.[2][5]